Regulatory T cells participate in CD39-mediated protection from renal injury.
CD39 is an ecto-enzyme that degrades extracellular nucleotides, such as ATP, and is highly expressed on by the vasculature and circulating cells including Foxp3+ regulatory T (Treg) cells. To study the role of purinergic regulation in renal disease, we used the adriamycin nephropathy (AN) mouse model of chronic renal injury, using human CD39-transgenic (hCD39Tg) and wild-type (WT) BALB/c mice. Effects of CD39 expression by Treg cells were assessed in AN by adoptive transfer of CD4(+) CD25(+)  and CD4(+) CD25(-)  T cells isolated from hCD39Tg and WT mice. hCD39Tg mice were protected from renal injury in AN with decreased urinary protein and serum creatinine, and significantly less renal injury compared with WT mice. While WT CD25(+)  and hCD39Tg CD25(-)  T cells conferred some protection against AN, hCD39Tg CD25(+)  Treg cells offered greater protection. In vitro studies showed direct pro-apoptotic effects of ATP on renal tubular cells. In conclusion, hCD39 expressed by circulating leukocytes and intrinsic renal cells limits innate AN injury. Specifically, CD39 expression by Treg cells contributes to its protective role in renal injury. These findings suggest that extracellular nucleotides mediate AN kidney injury and that CD39, expressed by Treg cells and other cells, is protective in this model.
Centre for Kidney Research, Children's Hospital at Westmead, Sydney, Australia.
Yuan Min
YM
Wang
Jennifer L
JL
McRae
Simon C
SC
Robson
Peter J
PJ
Cowan
Geoff Yu
GY
Zhang
Min
M
Hu
Tania
T
Polhill
Yiping
Y
Wang
Guoping
G
Zheng
Ya
Y
Wang
Vincent W S
VW
Lee
Robert J
RJ
Unwin
David C H
DC
Harris
Karen M
KM
Dwyer
Stephen I
SI
Alexander
D000255:Adenosine Triphosphate / Q000276:immunology / Q000378:metabolism; D000818:Animals; D015703:Antigens, CD / Q000276:immunology* / Q000378:metabolism*; D017209:Apoptosis / Q000276:immunology; D001081:Apyrase / Q000276:immunology* / Q000378:metabolism*; D003404:Creatinine / Q000276:immunology / Q000378:metabolism; D004195:Disease Models, Animal; D004317:Doxorubicin; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000276:immunology* / Q000378:metabolism; D007684:Kidney Tubules / Q000276:immunology / Q000378:metabolism; D007962:Leukocytes / Q000276:immunology / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000378:metabolism
D015703:Antigens, CD; D004317:Doxorubicin; D000255:Adenosine Triphosphate; D003404:Creatinine; D001081:Apyrase; C067869:CD39 antigen